Andexanet alfa

Drug Profile

Andexanet alfa

Alternative Names: AndexXa; AnXa; IndexXa; PRT-064445; PRT-4445; PRT-44545; Recombinant factor-Xa-Portola; rfXa-inhibitor-antidote

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator Portola Pharmaceuticals
  • Class Antidotes; Antihaemorrhagics; Disulfides; Recombinant proteins
  • Mechanism of Action Blood coagulation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemorrhage
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Haemorrhage

Most Recent Events

  • 03 Dec 2016 Efficacy data from a phase II trial in Haemorrhage presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Haemorrhage presented at the 58th Annual Meeting and Exposition of the American Society of Haematology
  • 07 Nov 2016 Portola Pharmaceuticals announces intention to resubmit BLA to US FDA in 2Q-2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top